These agreements are expected to add approximately 400 tons in 2024 and establish long-term production infrastructure. Expanding the number of seed producers in various geographies with whom the company currently works is expected to lower production risks. Casterra's high-yield castor seed varieties, developed with Evogene's GeneRator AI tech-engine, are rigorously tested to meet industry standards. They are distinguished by exceptional cleanliness, successful phytosanitary test results, and an exceptional ...

Conference call scheduled for 9:00 AM ET REHOVOT, Israel, Feb. 26, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that it will release its financial results for the third quarter of 2023, on Thursday, March 7th, 2024. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 ...

In collaboration with Bayer's Crop Science division, having an industry-leading R&D pipeline and portfolio of seeds & traits, crop protection, and digital farming solutions, AgPlenus will use its AI-driven computational modeling technology to design and optimize molecules identified for their broad-spectrum herbicidal activity targeting the APTH1 protein, a new mode of action identified by AgPlenus. Herbicide market is valued at $42.81 billion in 2024[1] and is crucial for ensuring global food security. It ...

Insects pose a major challenge to the health of crops worldwide, directly injuring plants as they feed on the plant's stems, fruit and roots, as well as indirectly by transmitting bacterial, viral and fungal infections to crops - costing the global economy an estimated $70 billion a year, according to the UN's Food and Agriculture Organization[1]. Experts predict such losses will worsen with global warming widening the spread of invasive insect risk and rising resistance to available insecticides. "Syngenta ...

The probiotics market is expected to double and reach approximately $114 billion by 2031 from approximately $55 billion in 2022[i]. The increased awareness of the microbiome, the bacteria living in and on the human body, has sparked significant interest in microbiome products based on supporting microbes for a healthier lifestyle. This collaboration aligns with the expanding importance of global microbiome research. The collaboration generates excellent synergy by combining Evogene's knowledge in bacterial- ...

Company Participants All forward-looking statements made herein speak only as of the date of the announcement of results. Many of the factors that impact whether forward-looking statements will come true are beyond the control of Evogene and may cause actual results to differ materially from anticipated results. We continued significant investment in Evogene ChemPass AI tech engine to strongly position us to forge strategic partnerships with industry leaders, expediting product development and delivering no ...

Financial Data and Key Metrics Changes - Revenues for the first quarter were $641,000 compared to $237,000 in the same period the previous year, primarily due to revenues recognized from the collaboration agreement of Evogene's subsidiary, AgPlenus, with Corteva and from sales of Canonic's medical cannabis products in Israel [35] - Net loss for the first quarter of 2023 was $7 million compared to a net loss of $9.1 million in the same period in the previous year [36] - Consolidated cash as of March 31, 2023, was approximately $28.8 million, excluding the $10 million investment in Biomica received in April 2023 [75] Business Line Data and Key Metrics Changes - Lavi Bio's product, Drivers, is a microbiome seed treatment that enhances yield in North America across 10 million acres, with plans to broaden sales into Canadian and European markets [64] - AgPlenus is focusing on developing new herbicides and has seen interest in its product pipeline, particularly the APH1 candidate [66] - Canonic launched 6 new second-generation products in Israel and is expanding its sales model to include licensing agreements [13][95] Market Data and Key Metrics Changes - The initial target market for Lavi Bio's bio-fungicide product is valued at $200 million, with a second product targeting a $500 million market [11] - The castor market, particularly for biofuel, is rapidly growing, and Castera is positioned to be a key player in that market [69] Company Strategy and Development Direction - The company aims to enter new business relationships for product development leveraging its tech engines, focusing on enhancing the robustness and attractiveness of its AI-driven tech engines [62][70] - The long-term plan includes realizing value by spinning out or IPO-ing one or more subsidiaries, depending on market conditions [99] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the demand for products exceeding supply and plans to ramp up production for the expected increase in sales next year [93] - The company is aware of the need to improve investor relations and plans to allocate more resources to this area [131] Other Important Information - The company has no bank debt and aims to maintain self-sufficiency financially for the foreseeable future [20][70] - Recent external investments in subsidiaries like Lavi Bio and Biomica validate the significant inherent value within these entities [71] Q&A Session Summary Question: What is the expected production for Lavi Bio in 2024? - Management indicated that they expect a few hundred tons a year in 2024, which will be inventory for sale [80] Question: How is the company addressing the stock price issue? - Management acknowledged the need for better communication with the market and plans to enhance investor relations activities [46][131] Question: Can you provide more details on the Phase I clinical trial for Biomica? - Management confirmed that approximately 12 patients are expected to be enrolled in the Phase I study, with several already participating [107]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F | ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | OR | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended December 31, 2022 | | | OR | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | | ☐ | SHELL COMPANY REPORT PURSUANT TO SECTION ...

Exhibit 99.2 EVOGENE LTD. 13 Gad Feinstein St., Park Rehovot P.O.B. 4173, Ness Ziona, 7414003, Israel PROXY STATEMENT 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS This Proxy Statement is being furnished in connection with the solicitation of proxies on behalf of the Board of Directors, or the Board, of Evogene Ltd., to which we refer as Evogene or the Company, to be voted at the 2023 Annual General Meeting of Shareholders of the Company, or the Meeting, and at any adjournment thereof, pursuant to the Notice ...

Start Time: 09:00 January 1, 0000 9:34 AM ET Evogene Ltd. (NASDAQ:EVGN) Q3 2022 Earnings Conference Call November 17, 2022, 09:00 AM ET Company Participants Ofer Haviv - President and CEO Yaron Eldad - CFO Conference Call Participants Kristen Kluska - Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by. Welcome to Evogene's Third Quarter 2022 Results Conference Call. All participants are at present in listen-only mode. Following management's formal presentation, instructions will be g ...